Boardroom Alpha
Meeting calendar
TVGN · Special meeting · Thursday, February 19, 2026

Tevogen Inc

5 nominees · 2 ballot items.

Vote to (1) approve an amendment to the 2024 Omnibus Incentive Plan to increase shares available for issuance by 100,000,000 and (2) approve an amendment to the certificate of incorporation to permit a reverse stock split of outstanding common stock at a ratio between 1-for-25 and 1-for-85 (Board recommends FOR both).

Market cap
$391M
1Y TSR
-74.6%
Board grade
D
Record date
Jan 21, 2026
Filing
DEF 14A
Meeting concluded · Feb 19, 2026

Follow how the vote landed and what changed on Tevogen Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot2

  1. 1

    Amendment to 2024 Omnibus Incentive Plan to Increase Shares Available for Issuance

    ManagementBoard: FOR

    Approve an amendment to the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan to increase the number of shares of common stock reserved for issuance under the plan by 100,000,000 shares (from 58,951,432 to 158,951,432).

    More detail

    This management proposal requests shareholder approval to amend Section 4.1 of the Company’s 2024 Omnibus Incentive Plan to increase the shares reserved for issuance by 100 million, from 58,951,432 to 158,951,432 (which, if approved, would be reflected as an Initial Share Limit of 140,000,000 shares plus annual increases). Management frames the amendment as necessary to recruit, retain, and motivate employees, directors, and consultants by enabling grants of restricted stock, RSUs, options, and other awards; it emphasizes long‑term equity incentives as a mechanism to align executive compensation with stockholder value creation. The Board explains that equity awards also provide voting alignment through restricted stock and that the amendment would preserve the Committee’s existing plan administration, anti‑repricing protections, clawback and forfeiture provisions, and limitations on liberal share recycling. The filing notes that, as of the record date, directors and officers beneficially owned a majority of voting shares (70.51%), which is relevant to dilution and control considerations. If the reverse stock split is implemented, the reserved share amount would be adjusted proportionately by the split ratio; the amendment itself is not contingent on approval of the reverse split. Vote mechanics are described: a majority of shares present and entitled to vote is required, with abstentions and broker non‑votes counted as against. The Board unanimously recommends a vote FOR, arguing the increment is essential for continuity of operations and long‑term compensation strategy. Key governance protections remain in the plan (e.g., no repricing without shareholder approval), but investors should weigh potential dilution from a 100 million share increase against the Company’s hiring and retention needs and recent equity grants to insiders.

  2. 2

    Amendment to Certificate of Incorporation to Effect a Reverse Stock Split

    ManagementBoard: FOR

    Approve an amendment to the Company’s certificate of incorporation to permit the Board, in its discretion, to effect a reverse stock split of issued and outstanding common stock at a ratio between 1-for-25 and 1-for-85, with the exact ratio and timing to be set by the Board (if at all).

    More detail

    This management proposal asks shareholders to approve an amendment to the Company’s certificate of incorporation authorizing the Board to effect, at its discretion, a reverse stock split of outstanding common stock at any ratio between 1‑for‑25 and 1‑for‑85, with the exact ratio and timing left to the Board. The Board’s stated purpose is to address a Nasdaq deficiency (average closing bid below $1.00 over 30 consecutive trading days) and thereby reduce the risk of delisting by increasing the per‑share trading price; the Board emphasizes that the approval gives it flexibility to select an appropriate ratio or to abandon the split if conditions change. The filing highlights potential benefits—improved marketability, broader investor appeal, and potential to regain Nasdaq compliance—but also thoroughly discloses risks, including the possibility that total market capitalization may decline, liquidity could be reduced, odd‑lot issues and higher transaction costs could arise, and the split may be viewed negatively by investors. The proposal would not change authorized shares or par value but would increase the pool of unissued authorized shares relative to outstanding shares, potentially easing future issuances and raising takeover/anti‑dilution considerations. Mechanics (treatment of fractional shares for cash, adjustment of RSUs, warrants, and preferred conversions) and tax consequences are described; the Board would implement the split by filing the certificate amendment if it elects to proceed. Approval standard is that votes cast FOR must exceed votes cast AGAINST; brokers have discretionary voting authority on this routine listing‑related item. The Board recommends a vote FOR, citing Nasdaq compliance and liquidity objectives, but notes no assurance the split will achieve its goals; investors should weigh the compliance rationale against dilution and liquidity tradeoffs and the Board’s retained discretion to select the ratio.

Director elections

Nominees on the ballot5

Independent
Tenure on this board
2.7 yrs
Also a director at
Livanova PLC (LIVN)
Ownership

Top institutional holders10

Latest 13F quarter
1VANGUARD CAPITAL MANAGEMENT LLC0.4%23,976$136K
2MORGAN STANLEY0.3%18,083$102K
3AQR CAPITAL MANAGEMENT LLC0.3%16,953$96K
4GOLDMAN SACHS GROUP INC0.2%14,163$80K
5FMR LLC0.2%9,826$56K
6JANE STREET GROUP, LLC0.1%7,351$42K
7Russell Investments Group, Ltd.0.1%6,532$37K
8JANE STREET GROUP, LLC0.1%3,824$22K
9Tower Research Capital LLC (TRC0.0%1,494$8K
10UBS Group AG0.0%924$5K
Filings

Tevogen Inc proxy statements and SEC reports

Annual & quarterly reports (10-K, 10-Q)
Proxy statements (DEF 14A)
Reference

Frequently asked questions

When is the Tevogen Inc 2026 special meeting?
Tevogen Inc (TVGN) holds its 2026 special shareholder meeting on Thursday, February 19, 2026.
What is the record date for the Tevogen Inc 2026 meeting?
The record date for the Tevogen Inc 2026 meeting is Wednesday, January 21, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Tevogen Inc's 2026 meeting?
The board is presenting 5 director nominees at the Tevogen Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Tevogen Inc 2026 meeting?
Shareholders will vote on 2 proposals at the Tevogen Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer